These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12914137)

  • 41. Decision makers' experiences of prioritisation and views about how to finance healthcare costs.
    Werntoft E; Edberg AK
    Health Policy; 2009 Oct; 92(2-3):259-67. PubMed ID: 19487042
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sickness certificates as a basis for decisions regarding entitlement to sickness insurance benefits.
    Söderberg E; Alexanderson K
    Scand J Public Health; 2005; 33(4):314-20. PubMed ID: 16087494
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Thinking broadly about costs and benefits in ecological management.
    Costanza R
    Integr Environ Assess Manag; 2006 Apr; 2(2):166-73. PubMed ID: 16646385
    [TBL] [Abstract][Full Text] [Related]  

  • 44. "Fiscally responsible, clinically sensitive" cost sharing: contain costs while preserving quality.
    Fendrick AM; Chernew ME
    Am J Manag Care; 2007 Jun; 13(6 Pt 2):325-7. PubMed ID: 17567232
    [No Abstract]   [Full Text] [Related]  

  • 45. [The Dental and Pharmaceutical Benefits Agency misinterpret its mission].
    Carlsson U
    Lakartidningen; 2010 Jun 30-Jul 20; 107(26-28):1717; discussion 1718. PubMed ID: 20701155
    [No Abstract]   [Full Text] [Related]  

  • 46. [A reply on subsidizing of antihypertensive agents: the problem is exceptional undertreatment of hypertension].
    Willenheimer R; Nyström F; Berggren B; Lindström T; Cizinsky S; Weiss L
    Lakartidningen; 2008 Oct 22-28; 105(43):3055-6. PubMed ID: 19024623
    [No Abstract]   [Full Text] [Related]  

  • 47. [Ethical analysis of the decision-making process in occupational health practice].
    Franco G
    Med Lav; 2005; 96(5):375-82. PubMed ID: 16711638
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Drug committees welcome the SBU hypertension report. A number of patients can be offered cost-effective, evidence-based therapy].
    Ohlsson O
    Lakartidningen; 2004 Dec; 101(49):3984-5. PubMed ID: 15633336
    [No Abstract]   [Full Text] [Related]  

  • 49. Making or losing money with participation in clinical trials: a decision analysis.
    Jacobs VR
    Onkologie; 2009 Jul; 32(7):411-6. PubMed ID: 19556819
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Using evidence in pain practice: Part II: Interpreting and applying systematic reviews and clinical practice guidelines.
    Chou R
    Pain Med; 2008; 9(5):531-41. PubMed ID: 18346061
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The humanizing of healthcare delivery. Tackling the high costs and closing the loopholes.
    Kerry J
    Healthc Leadersh Rep; 2004 Mar; 12(3):4-12. PubMed ID: 15106329
    [No Abstract]   [Full Text] [Related]  

  • 52. Decision-making in priority setting for medicines--a review of empirical studies.
    Vuorenkoski L; Toiviainen H; Hemminki E
    Health Policy; 2008 Apr; 86(1):1-9. PubMed ID: 17950484
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Physicians are barely supported in their clinical decisions].
    Henning R
    Lakartidningen; 1994 Mar; 91(12):1221-2. PubMed ID: 8189855
    [No Abstract]   [Full Text] [Related]  

  • 54. Value-based insurance design.
    Chernew ME; Rosen AB; Fendrick AM
    Health Aff (Millwood); 2007; 26(2):w195-203. PubMed ID: 17264100
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness and lung cancer clinical trials.
    Du W; Reeves JH; Gadgeel S; Abrams J; Peters WP
    Cancer; 2003 Oct; 98(7):1491-6. PubMed ID: 14508837
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Priority dilemmas in psoriasis care and visions of a future care in a group of administrators, politicians and professionals in northern Sweden.
    Uttjek M; Dufåker M; Stenberg B; Nygren L
    Health Policy; 2008 Aug; 87(2):203-16. PubMed ID: 18302973
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Designed delays versus rigorous pragmatic trials: lower carat gold standards can produce relevant drug evaluations.
    Maclure M; Carleton B; Schneeweiss S
    Med Care; 2007 Oct; 45(10 Supl 2):S44-9. PubMed ID: 17909382
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost of care and clinical condition in paediatric cystic fibrosis patients.
    Baumann U; Stocklossa C; Greiner W; von der Schulenburg JM; von der Hardt H
    J Cyst Fibros; 2003 Jun; 2(2):84-90. PubMed ID: 15463855
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Key principles for the improved conduct of health technology assessments for resource allocation decisions.
    Drummond MF; Schwartz JS; Jönsson B; Luce BR; Neumann PJ; Siebert U; Sullivan SD
    Int J Technol Assess Health Care; 2008; 24(3):244-58; discussion 362-8. PubMed ID: 18601792
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.